Current Issues in Bioavailability & Bioequivalence

The assessment of BA/BE of different drug products is based on the fundamental assumption that two products are equivalent when the rate and extent of absorption of the test drug does not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses. Should the rate of absorption actually differ between products, it would have to be intentional and reflected in the proposed product label and be clearly demonstrated that it is not essential in the attainment of effective body drug concentrations on chronic use or has been shown to be medically insignificant for the drug. In practice, equivalence is indicated when key pharmacokinetic parameters used to establish rate and extent of the test, and reference products fall within a preset confidence interval. The FDA declares a drug product to be therapeutically equivalent to the innovator product if it is pharmaceutically equivalent, i.e., same active ingredient, dosage form, strength and route of administration, and bioequivalent. Products that are therapeutically equivalent can be used interchangeably. Thus, BE studies are construed to be considered surrogates for comparative clinical trials for the assessment of therapeutic equivalence in safety and efficacy between two drug products.

  • Bioequivalence studies on various dose combinations
  • Bioequivalence criteria for inhaled corticosteroids
  • Enhanced oral bioavailability of hydrophobic drugs

Related Conference of Current Issues in Bioavailability & Bioequivalence

October 30-November 01, 2017
A B2B Networking & Global Knowledge Exchange Forum

Annual Congress on Emerging Orphan Drugs and  Rare Diseases

San Antonio, Texas, USA
April 20-21, 2018

4th International Conference on Antibiotics: R&D, B2B

Las Vegas, Nevada, USA
April 26-27, 2018

11th European Biosimilars Congress

Rome, Italy
May 07-09, 2018

15th Annual European Pharma Congress

Frankfurt, Germany
June 18-19, 2018

9th Global Experts Meeting on Neuropharmacology

Paris, France
June 20-22, 2018

7th World Congress on Mass Spectrometry

Rome, Italy
July 09-10, 2018

12th Global
Pharmacovigilance & Clinical Trials Summit

Sydney, Australia
July 16-18, 2018

5th World Congress on Green Chemistry and Green Engineering

Melbourne, Australia
July 16-18, 2018

15th Asia-Pacific Pharma Congress

Melbourne, Australia
Jul 30-Aug 01, 2018

10th World Congress on Pharmacology

Barcelona, Spain
September 13-14, 2018

8th World Congress on Chromatography

Prague, Czech Republic
September 24-26, 2018

7th International Conference on Clinical Trials

Chicago, USA
(10 Plenary Forums - 1 Event)
October 22-23, 2018

18th Annual Pharma Middle East Congress

Abu Dhabi, UAE
September 17-18,2018

7th Global Advances in Mass Spectrometry

Singapore
November 05-06, 2018

18th Annual Pharmaceutical Chemical Analysis Congress

Madrid, Spain

Current Issues in Bioavailability & Bioequivalence Conference Speakers

Recommended Sessions

Related Journals

Are you interested in